57 results about "Neo epitope" patented technology

The invention belongs to the technical field of immunodetection, and discloses a kit for detecting the ratio of proBDNF to maure BDNF based on structural dynamics guidance and a preparation method of the kit, the kit comprises a solid phase carrier and a detection reagent, the three antibodies are determined on the basis of full-length conformational kinetics analysis of brain-derived neurotrophic factors; the first capture antibody targets an innate disorder region (SEQ ID NO: 1) of a proBDNF propeptide region; the second capture antibody targets an innate disorder region (SEQ ID NO: 2) of a proBDNF propeptide region; the second capture antibody is a neo-epitope specific antibody, is specifically combined with an N terminal (SEQ ID NO: 2) exposed by maure BDNF enzyme digestion, and is combined with a free alpha-amino group strictly dependent on the first histidine; and the universal detection antibody is combined to a Loop 4 region (SEQ ID NO: 3) of the Mature structural domain. The problems of steric hindrance and cross reaction in traditional immunodetection are solved through a structural biology strategy, and accurate distinguishing and ratio quantification of proBDNF and maure BDNF are achieved.

To provide an easy method and a kit for detecting active IL-18 alone.SOLUTION: There are constructed a method and a kit for immunologically measuring active IL-18 alone by using an antibody which recognizes a neoepitope generated in association with activation of IL-18. Examinations were made by using a plurality of bodies which recognizes activation cross edges of IL-18 and a plurality of antibodies which specifically recognizes IL-18 and the inventors have found that the combination of a monoclonal antibody 9-10.2 which recognizes activation cross edges of IL-18 and a rabbit-derived polyclonal antibody which specifically recognizes IL-18 detects active IL-18 the most sensitively. The immunoassay and the measurement kit by that combination can detect active IL-18 in concentration as low as a pg level.SELECTED DRAWING: Figure 7

Contemplated treatments and methods produce substantially increased quantities of memory T-cells and a persistent immune response by subcutaneous and / or subdermal co-administration of (1) a vector comprising a recombinant nucleic acid that encodes a cancer associated epitope, a cancer specific epitope, and / or a neoepitope, (2) an immune stimulating cytokine, and (3) a checkpoint inhibitor. Most typically, the co-administration is performed at substantially the same location, preferably within 1-21 days from each other, and the vector is an adenoviral expression vector, for example, included in a viral particle such as an AdV5 virus with a deletion of the E2b gene.

The present invention provides neutralizing monoclonal antibodies targeting Nipah virus G protein and their uses, wherein the monoclonal antibodies can recognize Nipah virus G protein. The present invention uses NiV G protein as an antigen target, displays antigens on a ferritin nanoparticle platform to immunize mice, and screens out three monoclonal antibodies that can specifically bind to NiV G protein. Antibody epitope competition experiments found that the S1E2 and SB10 monoclonal antibodies among these three antibodies recognize new epitopes of NiV G protein that have not been reported before. In vitro neutralization experiments have demonstrated that these three antibodies have high in vitro neutralizing activity, and can neutralize both NiV-M and NiV-B strains, with the characteristics of high expression and good stability, and can be used to prepare virus detection products such as Nipah and Hendra or drugs for preventing and treating Nipah and Hendra virus diseases.

The present invention relates to methods for predicting whether peptides or polypeptides comprising disease specific amino acid modifications, in particular tumor-associated neo-antigens, comprise epitopes, in particular tumor-associated neo-epitopes, which are useful for immunotherapy such as for vaccination. The methods of the invention may be used, in particular, for the provision of vaccines which are specific for a patient's tumor and, thus, in the context of personalized cancer vaccines.

Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and / or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.

The present invention provides phagocytic particles for treating or preventing cancer in a subject, wherein the phagocytic particle comprises a core and a neoantigen construct tightly associated with the core, and wherein the neoantigen construct comprises a neoepitope peptide having an amino acid sequence corresponding to the amino acid sequence of a portion of a protein or peptide known or suspected to be expressed by a cancer cell in the subject, wherein the portion of the protein or peptide has at least one somatically mutated amino acid. The present invention also relates to an injectable pharmaceutical composition for treating or preventing cancer.

This invention belongs to the field of biomedical technology, specifically disclosing the application of a CTL epitope peptide derived from the neoantigen ESR1 or its encoded nucleic acid in the preparation of a drug for treating tumors. Through analysis of the COSMIC database, epitope prediction, and in vitro and in vivo immunomodulatory activity experiments, this invention identified an HLA-A2-restricted CTL epitope peptide derived from the neoantigen ESR1. This mutant epitope peptide originates from a high-frequency mutation of ESR1 and can effectively stimulate and induce the production of neotope-specific cytotoxic T lymphocytes, specifically distinguishing between wild-type and mutant sequences, and killing tumor cells expressing the mutant epitope, exhibiting good anti-tumor effects. The resulting drug for treating tumors may contain the CTL epitope peptide derived from the neoantigen ESR1 or its encoded nucleic acid, or may contain a T-cell receptor, chimeric antigen receptor, or its encoded nucleic acid that specifically recognizes the mutant epitope peptide, demonstrating good therapeutic potential and clinical application prospects.

The invention relates to the fields of immunology and molecular virology, in particular to the fields of prevention and treatment of RSV (Respiratory Syndrome Virus). Specifically, the invention provides a monoclonal antibody capable of specifically binding to a neoepitope on pre-F protein, and application of the monoclonal antibody to detection, prevention and / or treatment of RSV infection and / or diseases caused by the infection.

Effectiveness of a neoepitope-based immunotherapeutic composition against a tumor can be increased by predicting the surface presentation of the neoepitope bound to the HLA molecule of the tumor cell. Surface presentation levels of neoepitopes can be predicted by identifying any changes in omics data of the tumor cell that may affect the expression or surface trafficking of the HLA molecule and that may affect binding affinities of neoepitopes to the HLA molecule.

Disclosed herein are mannan nanogels as a novel vaccine delivery platform as well as a novel method of making a self-assembling mannan nanogel for in vivo delivery of therapeutic agents.

Systems and methods are presented that allow for determination and prediction of payload toxicity in therapeutic viruses. Disclosed herein are methods of determining payload toxicity of an expressed polypeptide in a cell, comprising: generating or procuring a plurality of expression vectors, each containing a different recombinant nucleic acid sequence that encodes a corresponding recombinant polypeptide; expressing the recombinant nucleic acid sequence in a plurality of host cells while culturing the host cells; sequencing the plurality of expression vectors after culturing the host cells; and correlating at least portions of the recombinant nucleic acid sequence with a toxicity measure.

The application provides preparation and application of a diagnostic monoclonal antibody for a new epitope of human neutrophil lipocalin (HNL). Two new HNL protein conformation epitopes and one new HNL linear epitope are designed and provided, and an anti-HNL antibody with higher binding affinity and better binding specificity is screened to combine the new epitopes. The anti-HNL antibody of the application can be used for preparation of an HNL detection reagent and kit, and has higher sensitivity and specificity when used for detecting HNL protein in a sample, and can be applied to distinguishing bacterial infection and viral infection.

The invention provides a nano antibody targeting a coronavirus N antigen and application of the nano antibody. Wherein the nano antibody or the antigen binding fragment comprises a heavy chain variable region, and the amino acid sequences of HCDR1, HCDR2 and HCDR3 of the heavy chain variable region are respectively shown as SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3. The nano antibody disclosed by the invention has specificity and broad-spectrum binding activity and can be specifically bound with SARS-CoV-2 and a mutant thereof, the binding capacity reaches picomole level, and the phenomena of missing detection and the like in clinical detection are avoided; the antigen binding epitope is a brand new epitope; the production cost is lower, and popularization and application are facilitated.

Disclosed herein relates to immunotherapeutic compositions comprising immunotherapeutic peptides comprising neoepitopes, polynucleotides encoding the immunotherapeutic peptides, antigen presenting cells comprising the immunotherapeutic peptides or polynucleotides, or T cell receptors specific for the neoepitopes. Also disclosed herein is use of the immunotherapeutic compositions.

Two or more peptides or polypeptides and an adjuvant for use in a method of inducing a tumor specific immune response, wherein the peptides or polypeptides have been identified by a method comprising: identifying a plurality of neoantigenic peptides for preparing a subject-specific immunogenic composition, each neoantigenic peptide comprising a tumor-specific neoepitope comprising a tumor-specific mutation, the method comprising: a. identifying a plurality of subject-specific tumor mutations in expressed genes of a subject having cancer by whole genome or whole exome nucleic acid sequencing of tumor and normal tissue samples from the subject, wherein the mutations are present in the genome of cancer cells of the subject but not in normal tissue from the subject; b. wherein when a mutation identified in step (a) is a point mutation: i. identifying a mutant peptide having the mutation identified in step (a), wherein said mutant peptide comprises a tumor-specific neoepitope which binds to a class I HLA protein with a greater affinity than a wild -type peptide; and has an IC50 less than 500 nm; c. wherein when a mutation identified in step (a) is a splice-site, frameshift, read-through or gene-fusion mutation: i. identifying a mutant polypeptide encoded by the mutation identified in step (a), wherein said mutant polypeptide comprises a tumor-specific neoepitope which binds to a class I HLA protein.

Systems and methods are presented that allow for selection of tumor neoepitopes that are then used to generate recombinant nucleic acids that encode one or more polytopes that are optimized for proper trafficking and processing. In preferred methods, the polytopes are encoded in a plasmid and / or a viral expression system for use as a therapeutic agent.

Disclosed herein are compositions comprising a plurality of iterations of an antigen-encoding nucleic acid sequence having an EGFR neoepitope encoding sequence. Also disclosed are nucleotides, cells and methods related to the compositions, including the use of the compositions as vaccines.

Effectiveness of a neoepitope-based immunotherapeutic composition against a tumor can be increased by predicting the surface presentation of the neoepitope bound to the HLA molecule of the tumor cell. Surface presentation levels of neoepitopes can be predicted by identifying any changes in omics data of the tumor cell that may affect the expression or surface trafficking of the HLA molecule and that may affect binding affinities of neoepitopes to the HLA molecule.

Described herein are methods of identifying immunologically protective neo-epitopes from the cancer tissue DNA of cancer patients using biophysical principles as well as bioinformatics techniques. The identification of immunologically protective neo-epitopes provides pharmaceutical compositions with a limited number of tumor-specific peptides suitable for personalized genomics-driven immunotherapy of human cancer. Specifically disclosed herein is a method of using the conformational stability of an epitope in an MHC protein-binding groove to predict immunogenicity of peptides in a putative neo-peptide set from a tumor from a cancer patient. Pharmaceutical compositions and methods of administration are also included.

The present invention relates to a method for selecting neoepitopes for an individual, by selecting MHC I and / or MHC II binding neoepitopes and ranking them with respect the methods as described herein.

A method and composition are provided herein, wherein a therapeutic agent comprising NK cells is administered to a cancer patient to induce the expression of MHC-I in a tumor, and subsequent treatment with T cells effectively targets tumor-associated antigens and neoepitopes presented by the newly expressed MHC-I in said tumor cells.

The disclosure provides a method for detection and quantification of amyloidogenic lambda free light chain (lFLC). The disclosure further provides reagents for performing the method, including monoclonal antibodies or antigen binding fragments thereof that bind to a neo-epitope on amyloidogenic λFLC exposed to limited proteolysis. The clinical utilities of the methods described herein include early detection in individuals suspected of plasma cell disorders (MGUS, SMM, MM, IgM-AL, and AL), differentiation from other amyloidosis such as ATTR, use in companion diagnostics, demonstration of target engagement, assessment of therapeutic response, detection of MRD, and detection of relapse.

The invention relates to a novel epitope of PTPRZ1, which has good immunogenicity and can be used for immunotherapy of cancer.

Compositions of peptides modified to improve HLA binding or T cell recognition while conserving reactivity to the target neoepitope, enhance activation of neoantigen-specific T cells. Methods of use include treating cancer by administering one or more of these peptides generated by computer modeling.

Provided is a modified peptide composition which is modified to enhance HLA binding or T cell recognition and improve activation of neoantigen-specific T cells while preserving reactivity to a target neoepitope. Methods of use include the treatment of cancer by administering one or more of these peptides generated by computer modeling.

A method for combining restrictive proteolysis and immunoassays to specifically detect and quantify amyloid-genic XFLC in a biological fluid. This method is accomplished by the use of mAbs that enable the detection and quantification of neoepitopes on dLCCD biomarkers produced after restricted proteolysis of ZFLC, which is very advantageous for kinetically unstable or amyloid-genic LFLC. The methods do not depend on FLC primary sequences in variable and constant domains, and can be used to detect and quantify up to 99% of human XFLC. The clinical utility of the assay includes early detection in individuals suspected of having plasma cell disorders (MGUS, SMM, MM, IgM-AL and AL), differentiation from other amyloidosis such as ATTR, use in companion diagnosis, proving of target conjugation, assessment of treatment response, detection of MRD, detection of recurrence. Assays, such as MSD, lateral flow, mass spectrometry, are also implemented that quantify the resulting dLCCD biomarkers and / or can further increase assay sensitivity.

An assay measuring protease mediated degradation of type IV collagen and its biomarker potential for identifying cancer patients with a T-cell permissive tumor microenvironment is described.